NRX PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$13M
↑+254.9% +$9Mvs FY2024
Total Liabilities
$29M
↑+7.5% +$2Mvs FY2024
Cash
$8M
↑+440.3% +$6Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $13M | $4M |
| Current Assets | $9M | $3M |
| Cash | $8M | $1M |
| ST Investments | $0 | $0 |
| Receivables | $161K | $0 |
| Inventory | $0 | $0 |
| Other Current | $934K | $2M |
| Non-Current Assets | $4M | $349K |
| PPE | $63K | $10K |
| Goodwill | $2M | $0 |
| Intangibles | $925K | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $1M | $339K |
| Total Liab+Eq | $13M | $4M |
| Current Liab. | $29M | $22M |
| Accounts Payable | $4M | $4M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $24M | $18M |
| Non-Current Liab. | $315K | $5M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $315K | $5M |
| Equity | $-16M | $-23M |
| Retained Earnings | $307M | $278M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · NRXP · Comparing FY2025 vs FY2024